Matthew Barcus
Stock Analyst at Chardan Capital
(2.85)
# 1,622
Out of 4,789 analysts
24
Total ratings
20.83%
Success rate
18.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.29 | +675.19% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $10.60 | +154.72% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.72 | +866.32% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $17.09 | +87.24% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.66 | +8,170.68% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.86 | +214.69% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $6.73 | +18.87% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $80 → $60 | $0.53 | +11,233.59% | 3 | Nov 17, 2022 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.29
Upside: +675.19%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $10.60
Upside: +154.72%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.72
Upside: +866.32%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $17.09
Upside: +87.24%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.66
Upside: +8,170.68%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.86
Upside: +214.69%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $6.73
Upside: +18.87%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $80 → $60
Current: $0.53
Upside: +11,233.59%